Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MLNR | O43193 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10363588 | 0.95 | RAB9A (0.39) | RAB9ACYP2D6TSHRCYP3A4TLR2 | |
| SCHEMBL3714016 | 0.95 | RAB9A (0.39) | RAB9ACYP2D6TSHRCYP3A4TLR2 | |
| SCHEMBL13728121 | 0.89 | ADRB2 (0.36) | SLC6A3SLC6A2SLC6A4CYP2D6TSHR | |
| SCHEMBL19034572 | 0.86 | SLC6A3 (0.36) | SLC6A3SLC6A2SLC6A4CYP2D6TSHR | |
| SCHEMBL8840314 | 0.84 | PRCP (0.39) | CYP2D6CYP3A4TLR2MEN1KMT2A | |
| SCHEMBL17732291 | 0.83 | PRCP (0.38) | CYP2D6CYP3A4TLR2CYP1A2PRCP | |
| SCHEMBL1263537 | 0.81 | TLR2 (0.35) | CYP2D6TSHRCYP3A4TLR2CYP1A2 | |
| SCHEMBL135813 | 0.81 | SLC6A2 (0.44) | SLC6A3SLC6A2SLC6A4MEN1KMT2A | |
| SCHEMBL1929065 | 0.81 | SLC6A2 (0.44) | SLC6A3SLC6A2SLC6A4MEN1KMT2A | |
| SCHEMBL3164291 | 0.81 | SLC6A2 (0.44) | SLC6A3SLC6A2SLC6A4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232559-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-10-04 | — | — | US | claimed |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2023-08-17 | — | — | US | disclosed |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
| US-11633479-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11612657-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-03-28 | — | — | US | disclosed |
| US-11382979-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-07-12 | — | — | US | disclosed |
| US-20220175929-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2022-06-09 | — | — | US | disclosed |
| US-20220175928-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2022-06-09 | — | — | US | disclosed |
| US-20220175930-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2022-06-09 | — | — | US | disclosed |
| US-9682922-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9463247-B2 | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160009637-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2016-01-14 | — | — | US | disclosed |
| US-20150306039-A1 | IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS | BANK OF AMERICA, N.A. | 2015-10-29 | — | — | US | disclosed |
| US-20150273068-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | BANK OF AMERICA, N.A. | 2015-10-01 | — | — | US | disclosed |
| US-9061063-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-9012498-B2 | Biodegradable lipids for the delivery of active agents | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20150005363-A1 | Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents | BANK OF AMERICA, N.A. | 2015-01-01 | — | — | US | disclosed |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120027803-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005363-A1 | Branched Alkyl And Cycloalkyl Terminated Biodegradable Lipids For The Delivery Of Active Agents | LIPA, CETP, APOB | RAB9A 4354/4885SLC6A3 3771/4885SLC6A2 2255/4885 |
| US-20120027803-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, CETP, APOB | RAB9A 4030/4885SLC6A3 3619/4885SLC6A2 1922/4885 |
| US-20160009637-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, CETP, APOB | RAB9A 4030/4885SLC6A3 3619/4885SLC6A2 1922/4885 |
| US-20220175929-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | RAB9A 3955/4885SLC6A3 3622/4885SLC6A2 1960/4885 |
| US-11612657-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | RAB9A 3955/4885SLC6A3 3622/4885SLC6A2 1960/4885 |
| US-11633479-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | RAB9A 3955/4885SLC6A3 3622/4885SLC6A2 1960/4885 |
| US-20130195920-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | RAB9A 3955/4885SLC6A3 3622/4885SLC6A2 1960/4885 |
| US-11382979-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | RAB9A 3955/4885SLC6A3 3622/4885SLC6A2 1960/4885 |
| US-20150273068-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | RAB9A 3955/4885SLC6A3 3622/4885SLC6A2 1960/4885 |
| US-20220175930-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | RAB9A 3955/4885SLC6A3 3622/4885SLC6A2 1960/4885 |
| US-20070232559-A1 | 2-PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY AND COMPOSITIONS THEREOF | ADORA2A, ADORA3, ADORA1 | RAB9A 1308/4885SLC6A3 832/4885SLC6A2 786/4885 |
| US-20220175928-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | RAB9A 3955/4885SLC6A3 3622/4885SLC6A2 1960/4885 |
| US-11679158-B2 | Biodegradable lipids for the delivery of active agents | LIPA, APOB, CETP | RAB9A 3955/4885SLC6A3 3622/4885SLC6A2 1960/4885 |
| US-20230256098-A1 | BIODEGRADABLE LIPIDS FOR THE DELIVERY OF ACTIVE AGENTS | LIPA, APOB, CETP | RAB9A 3955/4885SLC6A3 3622/4885SLC6A2 1960/4885 |
| US-20150306039-A1 | IMPROVED NUCLEIC ACID LIPID PARTICLE FORMULATIONS | LIPA, NPC1L1, CETP | RAB9A 1798/4885SLC6A3 3023/4885SLC6A2 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.